- Home
- PFLT vs IMTXW Comparison
PFLT vs IMTXW Comparison
Compare PFLT & IMTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- IMTXW
- Stock Information
- Founded
- PFLT 2010
- IMTXW N/A
- Country
- PFLT United States
- IMTXW Germany
- Employees
- PFLT N/A
- IMTXW 343
- Industry
- PFLT Finance: Consumer Services
- IMTXW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFLT Finance
- IMTXW Health Care
- Exchange
- PFLT Nasdaq
- IMTXW Nasdaq
- Market Cap
- PFLT 838.8M
- IMTXW N/A
- IPO Year
- PFLT N/A
- IMTXW N/A
- Fundamental
- Price
- PFLT $11.46
- IMTXW $1.18
- Analyst Decision
- PFLT Strong Buy
- IMTXW
- Analyst Count
- PFLT 2
- IMTXW 0
- Target Price
- PFLT $12.00
- IMTXW N/A
- AVG Volume (30 Days)
- PFLT 635.8K
- IMTXW N/A
- Earning Date
- PFLT 11-25-2024
- IMTXW N/A
- Dividend Yield
- PFLT 10.71%
- IMTXW N/A
- EPS Growth
- PFLT N/A
- IMTXW N/A
- EPS
- PFLT 1.60
- IMTXW N/A
- Revenue
- PFLT $166,565,000.00
- IMTXW N/A
- Revenue This Year
- PFLT $29.07
- IMTXW N/A
- Revenue Next Year
- PFLT $14.55
- IMTXW N/A
- P/E Ratio
- PFLT $7.18
- IMTXW N/A
- Revenue Growth
- PFLT 25.81
- IMTXW N/A
- 52 Week Low
- PFLT $9.69
- IMTXW N/A
- 52 Week High
- PFLT $12.63
- IMTXW N/A
- Technical
- Relative Strength Index (RSI)
- PFLT 43.78
- IMTXW N/A
- Support Level
- PFLT $11.67
- IMTXW N/A
- Resistance Level
- PFLT $11.90
- IMTXW N/A
- Average True Range (ATR)
- PFLT 0.14
- IMTXW 0.00
- MACD
- PFLT -0.01
- IMTXW 0.00
- Stochastic Oscillator
- PFLT 6.32
- IMTXW 0.00
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About IMTXW Immatics N.V.
Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.